Epirubicin: clinical trials recruiting now
18
Recruiting trials
15
Conditions studied
25
US states with sites
41
Countries
FDA drug label
- FDA-approved
- Yes. Epirubicin appears in the FDA drug-label database. Marketed as Ellence.
- Boxed warning
- The FDA label for Epirubicin carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] . ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ).
Phase breakdown
Phase 1 2
Phase 2 11
Phase 3 5
Phase 4 2
Conditions being studied
Recruiting trials involving Epirubicin
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
- A Study for the Adjuvant Treatment of Breast Cancer
- A Study for the Neoadjuvant Treatment of Breast Cancer
- EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- MicroRNA Profiles in Triple Negative Breast Cancer
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
- Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Common questions
Is Epirubicin FDA-approved?
Yes, marketed as Ellence. Its FDA label carries a boxed warning.
How many recruiting trials involve Epirubicin?
18 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.